Madam Therapeutics

News Archive

AMR Industry Alliance announces to fight antimicrobial resistance

An international association of pharmaceutical, biotechnology, and diagnostics companies today announced the formation of a new alliance to monitor and drive industry efforts to fight antimicrobial resistance (AMR). The AMR Industry Alliance aims to bring together stakeholders from the life sciences industry to ensure progress is made on their commitments to reduce the development of antimicrobial resistance, invest in research and development, and improve global access to antimicrobials, diagnostic tests, and vaccines. Read more….

Leonie de Best, CBO of Madam Therapeutics, is in Paris to engage in B2B meetings at BioEquity Europe 2017

Leonie de Best, CBO of Madam Therapeutics, traveled to Paris today to be at the BioEquity Europe 2017 meeting, which is held 22-23rd May. If you are attending the conference and would like to book an appointment to meet with us, please email us on info@madam-therapeutics.com

 

Antibiotic resistance has a language problem -standardize the terminology for a better global response

Clinicians have long known that microbes such as bacteria, viruses and fungi are becoming alarmingly resistant to the medicines used to treat them. But a global response to this complex health threat — commonly termed ‘antimicrobial resistance’ — requires engagement from a much broader array of players, from governments, regulators and the public, to experts in health, food, the environment, economics, trade and industry.

A recent editorial in Nature, describes that people from these disparate domains are talking past each other. Many of the terms routinely used to describe the problem are misunderstood, interpreted differently or loaded with unhelpful connotations.

A 2015 survey by the World Health Organization (WHO) in 12 countries highlighted people’s unfamiliarity with the language of antibiotic resistance2. Fewer than half of the nearly 10,000 respondents had heard of the term ‘antimicrobial resistance’. Only one-fifth were aware of its abbreviated form ‘AMR’. By contrast, more than two-thirds knew of the terms ‘antibiotic resistance’ or ‘drug resistance’. A similar study published the same year of people in the United Kingdom — by the UK biomedical charity the Wellcome Trust — revealed comparable trends

The interchangeable use of terms by the press and by scientists in publications and meetings is likely to be counterproductive in all sorts of contexts. Take food production. In recent years, different sectors have called on countries to phase out or abolish the ‘antimicrobials’ used to promote animal growth, to protect humans from increasing levels of drug-resistant bacteria4.

Simple, clear and unambiguous terminology would help to ensure that the global effort against drug resistance is focused on the greatest immediate challenge: the rise of drug-resistant bacteria that cause common illnesses, resulting from the high use of antibiotics by humans. It could also improve people’s understanding and engagement.

Read more

Madam Therapeutics at the 18th BioEquity Europe Meeting, Paris, France

Madam Therapeutics will be at the BioEquity Europe 2017 meeting, to be held between the 22-23rd May in Paris, France. If you are attending the conference and would like to book an appointment to meet with us, please email us on info@madam-therapeutics.com

Madam Therapeutics has been nominated for Most Innovative Antibiotic Treatment Company by European CEO Magazine

Madam Therapeutics has been nominated for Most Innovative Antibiotic Treatment Company  2017 by European CEO Magazine. With this award, they celebrate leading players across a range of sectors. Announcement of the European CEO 2017 award winners will be made early January 2018.

US patent No. 9,562,085 grant for SAAP-10.

Madam Therapeutics is proud to announce that the United States of America patent for SAAP-10 was granted on 7 February 2017 bearing patent No. 9,562,085. The patent assignment for our lead peptide SAAP-148 is anticipated in 6 months time.

NADP takes the next step towards new antibiotics and alternatives

 

The Netherlands Antibiotic Development Platform (NADP) will be launched in April. The new platform facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.

NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties. At a later stage, the NADP will provide Drug Discovery Management support/vouchers and Intellectual Property and Technology Transfer Office support.

Within the Netherlands Antibiotic Development Platform (NADP), knowledge institutions and the business community will work together to develop new antibiotics and alternatives. The core mission of NADP is to bring companies and research groups together to accelerate research into the development of new antibiotics and alternatives to antibiotics.

Madam Therapeutics welcomes this very important initiative in the Netherlands, and congratulates the initiators with this achievement. In the upcoming years, Madam Therapeutics will contribute this expertise to the NADP to accelerate the R&D in new antibiotics, and alternative and preventive treatments for bacterial infections in humans and animals.

BioWorld Today: Antimicrobial peptides (AMPs) are amongst the most exiting developments in the antimicrobial development space today

BioWorld Today, one of the leading news sites for the biotech industry from Thomson Reuters, has labelled Antimicrobial peptides (AMPs), such as SAAP-148 that is developed by Madam Therapeutics, as one of the exiting developments in the anti-microbial development space.

“Antimicrobial resistance (AMR) is a topic that just won’t go away, and for good reason”, according to BioWorld. “Despite the plethora of threats facing humankind, including thousands of diseases in need of therapies or cures, many scientists worry that the biggest risk of extinction comes from the deadly pathogens that exist in uneasy cohabitation on planet Earth”.

Tensions mounted in 2015 after the mcr-1 gene was detected on plasmids in China and Europe and were heightened last year with the first U.S. case of a patient with an infection resistant to a last-resort antibiotic. But academics remain hard at work, and more small companies are moving into the space. Antimicrobial peptides (AMPs) – like SAAP-148- in particular – are among the newest kids on the block.

BioWorld Today highlights that AMPs have shown the ability to kill a broad spectrum of gram-negative and gram-positive bacteria, enveloped viruses, fungi and even cancerous cells. AMPs also may offer the prospect of enhancing immunity by functioning as immunomodulators.

WHO: Urgent need for new antimicrobials

Antimicrobial resistance (AMR) is a topic that just won’t go away, and for good reason. Despite the plethora of threats facing humankind, including thousands of diseases in need of therapies or cures, many scientists worry that the biggest risk of extinction comes from the deadly pathogens that exist in uneasy cohabitation on planet Earth.

Tensions mounted in 2015 after the mcr-1 gene was detected on plasmids in China and Europe and were heightened last year with the first U.S. case of a patient with an infection resistant to a last-resort antibiotic.

It is therefore of great importance that WHO has published its first ever list of antibiotic-resistant “priority pathogens” – a catalogue of 12 families of bacteria that pose the greatest threat to human health. The list was drawn up in a bid to guide and promote research and development (R&D) of new antibiotics, as part of WHO’s efforts to address growing global resistance to antimicrobial medicines.

The list highlights in particular the threat of gram-negative bacteria that are resistant to multiple antibiotics. These bacteria have built-in abilities to find new ways to resist treatment and can pass along genetic material that allows other bacteria to become drug-resistant as well.

Especially small companies like Madam Therapeutics are are moving into the space. Antimicrobial peptides (AMPs) such as SAAP-148 are among the newest kids on the block.

SAAP-148 have shown the ability to kill gram-negative and gram-positive bacteria, enveloped
viruses, fungi and even cancerous cells. AMPs also may offer the prospect of enhancing immunity by functioning as immunomodulators.

Knowledge of citizens on antimicrobial resistance across the EU remains low

There is a clear need for wide-reaching factual information programmes on AMR according to several recent surveys on consumer perceptions and awareness of antimicrobial resistance (AMR). This points to the growing need for greater understanding and demonstrates that science-based information should be one of the main points of action for the upcoming EU Action Plan to combat antimicrobial resistance, says IFAH-Europe.

The European Food Safety Authority’s recently published report on Perceptions on the human health impact of and antibiotics use in animals across the EU echoes the findings of the Commission’s Eurobarometer on Antimicrobial Resistance awareness, which showed that knowledge of citizens across the EU remains low.

Indeed these findings concur with IFAH-Europe’s citizens’ survey carried out in 2016 which showed that 69% of respondents have concerns about antibiotic-resistant bacteria from farm animals being passed to people and 49% think that the use of antibiotics in farm animals makes antibiotics less effective for people. EFSA’s report shows that 57% of respondents said they did not receive any information about resistance to antibiotics over the past year and 61% said that they don’t have enough knowledge about the use of antibiotics in farmed animals.